

Iain C Macdougall

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1963718/iain-c-macdougall-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

229
papers

11,741
citations

58
h-index

103
g-index

252
ext. papers

13,730
ext. citations

7.4
avg, IF

6.59
L-index

#	Paper	IF	Citations
229	The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia.. <i>Kidney International Reports</i> , 2022 , 7, 322-326	4.1	1
228	Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial.. <i>Scientific Reports</i> , 2022 , 12, 6853	4.9	0
227	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021 ,	59.2	15
226	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021 ,	59.2	14
225	Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	3
224	Nomenclature in nephrology: preserving 'renal' and 'nephro' in the glossary of kidney health and disease. <i>Journal of Nephrology</i> , 2021 , 34, 639-648	4.8	2
223	MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS. <i>Nephrology Dialysis Transplantation</i> , 2021 , 36,	4.3	1
222	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. <i>Kidney International</i> , 2021 , 100, 1101-1111	9.9	4
221	Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney International</i> , 2021 , 99, 1280-1295	9.9	18
220	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. <i>Health Technology Assessment</i> , 2021 , 25, 1-52	4.4	4
219	Feasibility Trial of Cognitive Behavioral Therapy for Fatigue in Hemodialysis (BReF Intervention). <i>Journal of Pain and Symptom Management</i> , 2021 , 61, 1234-1246.e5	4.8	2
218	The PrEscription of intraDialytic exercise to improve quALity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1345-1355	4.5	4
217	Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. <i>Annals of Medicine</i> , 2021 , 53, 274-285	1.5	7
216	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
215	Preoperative intravenous iron for anaemia in elective major open abdominal surgery: the PREVENTT RCT. <i>Health Technology Assessment</i> , 2021 , 25, 1-58	4.4	3
214	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. <i>JACC: Heart Failure</i> , 2021 , 9, 518-527	7.9	1
213	Iron Deficiency in CKD Without Concomitant Anemia. <i>Kidney International Reports</i> , 2021 , 6, 2752-2762	4.1	0

212	Randomized Trial-PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis. <i>Kidney International Reports</i> , 2021 , 6, 2159-2170	4.1	4
211	Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.. <i>Kidney360</i> , 2021 , 2, 1761-1769	1.8	1
210	The ASCEND-ND trial: Study design and participant characteristics. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	1
209	Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2020 , 51, 493-500	4.6	5
208	Intravenous iron: a framework for changing the management of iron deficiency. <i>Lancet Haematology,the</i> , 2020 , 7, e342-e350	14.6	28
207	A prospective study of fatigue trajectories among in-centre haemodialysis patients. <i>British Journal of Health Psychology</i> , 2020 , 25, 61-88	8.3	7
206	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1654	12.7	1
205	P0858A MULTICENTRE PROSPECTIVE DOUBLE BLIND RANDOMISED CONTROLLED TRIAL OF INTRAVENOUS IRON IN IRON DEFICIENT BUT NOT ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE ON FUNCTIONAL STATUS. <i>Nephrology Dialysis Transplantation</i> , 2020 , 35,	4.3	1
204	Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. <i>Lancet, The</i> , 2020 , 396, 1353-1361	40	86
203	Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. <i>Advances in Therapy</i> , 2020 , 37, 1960-2002	4.1	3
202	Iron Administration, Infection, and Anemia Management in CKD: Untangling the Effects of Intravenous Iron Therapy on Immunity and Infection Risk. <i>Kidney Medicine</i> , 2020 , 2, 341-353	2.8	14
201	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1118-1127	12.7	33
200	Treatment of anaemia in end-stage renal disease: A double-edged iron sword?. <i>EBioMedicine</i> , 2019 , 40, 31-32	8.8	7
199	Intravenous Iron Use in the Care of Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1528-1530	6.9	1
198	Obesity and recovery from acute kidney injury (Ob AKI): a prospective cohort feasibility study. <i>BMJ Open</i> , 2019 , 9, e024033	3	8
197	Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial?. <i>Clinical Nephrology</i> , 2019 , 91, 237-245	2.1	9
196	Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. <i>American Journal of Nephrology</i> , 2019 , 49, 271-280	4.6	26
195	Fatigue in Prevalent Haemodialysis Patients Predicts All-cause Mortality and Kidney Transplantation. <i>Annals of Behavioral Medicine</i> , 2019 , 53, 501-514	4.5	13

194	Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease. <i>Nephron</i> , 2019 , 143, 243-254	3.3	17
193	Renal cell carcinoma in kidney transplant recipients at Guy's and King's College Hospital (UK) between 1987-2018.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16066-e16066	2.2	
192	Effects of Molidustat in the Treatment of Anemia in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 28-39	6.9	51
191	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019 , 380, 447-458	59.2	187
190	Mortality and morbidity following exercise-based renal rehabilitation in patients with chronic kidney disease: the effect of programme completion and change in exercise capacity. <i>Nephrology Dialysis Transplantation</i> , 2019 , 34, 618-625	4.3	31
189	HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics. <i>Pediatric Nephrology</i> , 2019 , 34, 365-378	3.2	16
188	Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?. <i>American Journal of Nephrology</i> , 2018 , 47, 72-83	4.6	45
187	Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. <i>American Journal of Hematology</i> , 2018 , 93, 683-690	7.1	70
186	'It's when you're not doing too much you feel tired': A qualitative exploration of fatigue in end-stage kidney disease. <i>British Journal of Health Psychology</i> , 2018 , 23, 311-333	8.3	13
185	Intravenous iron: out of sight, out of mind. <i>Lancet Haematology</i> , 2018 , 5, e10-e12	14.6	10
184	SP334IRON REGULATION BY MOLIDUSTAT, BAY 85-3934, A DAILY ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR IN PATIENTS WITH CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, i457-i457	4.3	2
183	A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia". <i>American Journal of Hematology</i> , 2018 , 93, E232-E233	7.1	233
182	Iron therapy for managing anaemia in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2018 , 27, 358-363	3.5	1
181	A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 1628-1635	4.3	19
180	Cognitive-behavioural therapy (CBT) for renal fatigue (BRef): a feasibility randomised-controlled trial of CBT for the management of fatigue in haemodialysis (HD) patients. <i>BMJ Open</i> , 2018 , 8, e020842	3	8
179	Randomized trial of intravenous iron-induced hypophosphatemia. <i>JCI Insight</i> , 2018 , 3,	9.9	80
178	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018 , 48, 260-268	4.6	21
177	Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. <i>American Journal of Therapeutics</i> , 2018 , 25, e670-e674	1	2

176	Reliability and validity of the five-repetition sit-to-stand test in adult kidney transplant recipients. <i>International Journal of Therapy and Rehabilitation</i> , 2018 , 25, 158-166	0.4	2
175	Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. <i>BMC Nephrology</i> , 2017 , 18, 24	2.7	11
174	Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients. <i>American Journal of Nephrology</i> , 2017 , 45, 187-199	4.6	82
173	Examining the efficacy of social-psychological interventions for the management of fatigue in end-stage kidney disease (ESKD): a systematic review with meta-analysis. <i>Health Psychology Review</i> , 2017 , 11, 197-216	7.1	15
172	Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. <i>Kidney International</i> , 2017 , 92, 47-66	9.9	168
171	IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 7083-7088	11.5	48
170	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017 , 92, 1068-1078	7.1	168
169	The available intravenous iron formulations: History, efficacy, and toxicology. <i>Hemodialysis International</i> , 2017 , 21 Suppl 1, S83-S92	1.7	77
168	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1530-1539	4.3	30
167	Measurement of hepcidin isoforms in human serum by liquid chromatography with high resolution mass spectrometry. <i>Bioanalysis</i> , 2017 , 9, 541-553	2.1	14
166	Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. <i>Journal of Blood Medicine</i> , 2017 , 8, 155-163	2.3	8
165	Behavioural change and exercise therapy for patients with CKD. <i>Journal of Kidney Care</i> , 2017 , 2, 58-65	0.1	
164	The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, 79-88	4.5	26
163	New options for the anemia of chronic kidney disease. <i>Kidney International Supplements</i> , 2017 , 7, 157-163	3	22
162	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017 , 136, 1374-1383	16.7	179
161	The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. <i>BMC Nephrology</i> , 2017 , 18, 117	2.7	5
160	Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. <i>Nephrology</i> , 2017 , 22, 969-976	2.2	19
159	Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. <i>CKJ: Clinical Kidney Journal</i> , 2017 , 10, i16-i24	4.5	34

158	Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial?. <i>Clinical Nephrology</i> , 2017 , 88, 301-310	2.1	12
157	Iron Supplementation: What's New?. <i>Blood</i> , 2017 , 130, SCI-43-SCI-43	2.2	1
156	Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients - A pilot randomised controlled trial. <i>PLoS ONE</i> , 2017 , 12, e0171063	3.7	19
155	MP415EFFECT OF INTRAVENOUS IRON THERAPY WITH FERRIC CARBOXYMALTOSSE ON OUTCOMES IN IRON-DEFICIENT PATIENTS WITH RENAL DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF FOUR RANDOMIZED, DOUBLE-BLIND TRIALS. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, iii581-iii581	4.3	1
154	Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome. <i>Journal of General Internal Medicine</i> , 2016 , 31, 353-6	4	7
153	Iron deficiency anaemia. <i>Lancet, The</i> , 2016 , 387, 907-16	4.0	611
152	Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1421-6	4.1	26
151	Does Intra-gastric Balloon Treatment for Obesity in Chronic Kidney Disease Heighten Acute Kidney Injury Risk?. <i>American Journal of Nephrology</i> , 2016 , 44, 411-418	4.6	6
150	Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial. <i>BMC Nephrology</i> , 2016 , 17, 177	2.7	22
149	Psychosocial and Clinical Correlates of Fatigue in Haemodialysis Patients: the Importance of Patients' Illness Cognitions and Behaviours. <i>International Journal of Behavioral Medicine</i> , 2016 , 23, 271-281	2.6	30
148	Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients. <i>PLoS ONE</i> , 2016 , 11, e0148938	3.7	19
147	SO036MOLIDUSTAT INCREASES HAEMOGLOBIN IN ERYTHROPOIESIS STIMULATING AGENTS (ESA)-NAIVE ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS (CKD-ND). <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, i16-i16	4.3	5
146	Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. <i>PLoS ONE</i> , 2016 , 11, e0157063	3.7	22
145	SP311A MODEL TO PREDICT HAEMATOPOIETIC NON-RESPONSE TO ORAL IRON IN PATIENTS WITH NON-DIALYSIS DEPENDENT CKD (ND-CKD): AN ANALYSIS FROM THE FIND-CKD TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, i193-i194	4.3	7
144	SP555IMPROVING ANAEMIA THERAPY IN HAEMODIALYSIS PATIENTS: RESULTS OF A MULTICENTRE CLINICAL AUDIT. <i>Nephrology Dialysis Transplantation</i> , 2016 , 31, i277-i277	4.3	
143	Iron Treatment Strategies in Nondialysis CKD. <i>Seminars in Nephrology</i> , 2016 , 36, 99-104	4.8	3
142	Measuring fatigue in haemodialysis patients: The factor structure of the Chalder Fatigue Questionnaire (CFQ). <i>Journal of Psychosomatic Research</i> , 2016 , 84, 81-83	4.1	18
141	Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?. <i>European Journal of Heart Failure</i> , 2015 , 17, 248-62	12.3	85

140	Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 451-60	4.3	57
139	Aerobic or Resistance Training and Pulse Wave Velocity in Kidney Transplant Recipients: A 12-Week Pilot Randomized Controlled Trial (the Exercise in Renal Transplant [ExeRT] Trial). <i>American Journal of Kidney Diseases</i> , 2015 , 66, 689-98	7.4	61
138	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. <i>European Journal of Heart Failure</i> , 2015 , 17, 329-39	12.3	62
137	Risk for chronic kidney disease increases with obesity: Health Survey for England 2010. <i>Public Health Nutrition</i> , 2015 , 18, 3349-54	3.3	20
136	Participation in a Structured Weight Loss Program and All-Cause Mortality and Cardiovascular Morbidity in Obese Patients With Chronic Kidney Disease. <i>Journal of Renal Nutrition</i> , 2015 , 25, 472-9	3	13
135	Supplemental iron via dialysate: a novel mode of delivery for hemodialysis patients. <i>Kidney International</i> , 2015 , 88, 946-9	9.9	1
134	Effect of exercise training on estimated GFR, vascular health, and cardiorespiratory fitness in patients with CKD: a pilot randomized controlled trial. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 425-34	7.4	104
133	Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 414-26	2.6	17
132	On the safety of intravenous iron, evidence trumps conjecture. <i>Haematologica</i> , 2015 , 100, e214-5	6.6	34
131	Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure. <i>Croatian Medical Journal</i> , 2015 , 56, 531-41	1.6	5
130	New data on the safety of IV iron-but why the discrepancy with FIND-CKD?. <i>Kidney International</i> , 2015 , 88, 1445-1446	9.9	7
129	A randomized, open-label trial of iron isomaltoside 1000 (Monofer [®]) compared with iron sucrose (Venofer [®]) as maintenance therapy in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30, 1577-89	4.3	49
128	Intravenous iron therapy in non-dialysis CKD patients. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 717-20	4.5	5
127	Desmopressin use prior to renal transplant biopsy-does it fit?. <i>CKJ: Clinical Kidney Journal</i> , 2014 , 7, 602-4	4.5	10
126	Weight loss, adipokines, and quality of life after sleeve gastrectomy in obese patients with stages 3-4 CKD: a randomized controlled pilot study. <i>American Journal of Kidney Diseases</i> , 2014 , 64, 660-3	7.4	22
125	Renal rehabilitation: the benefits, barriers and exercise options. <i>Journal of Renal Nursing</i> , 2014 , 6, 29-33		
124	Unusual presentation of aortic dissection with bilateral testicular pain and rapidly deteriorating renal function. <i>Urology</i> , 2014 , 83, 989-91	1.6	
123	FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 2075-84	4.3	173

122	The authors reply. <i>Kidney International</i> , 2014 , 86, 211	9.9	
121	The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 843-50	4.3	27
120	A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 705-12	6.9	70
119	Regulatory and clinical considerations for biosimilar oncology drugs. <i>Lancet Oncology</i> , 2014 , 15, e594-e605	21.7	86
118	Safety of intravenous iron formulations: facts and folklore. <i>Blood Transfusion</i> , 2014 , 12, 296-300	3.6	52
117	Comparison of Safety Reports to the FDA from a Pilot Introduction of Peginesatide, a Third Generation Erythropoiesis Stimulating Agent Versus Those from the Usual Care Setting: Manufacturers of Biosimilars and the FDA Should Consider Pilot Introductions of These Agents. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014 , 39, 251-257	2.2	
116	Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2013 , 4, 247-57	10.3	22
115	An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. <i>Journal of Medical Economics</i> , 2013 , 16, 108-14	2.4	14
114	Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. <i>New England Journal of Medicine</i> , 2013 , 368, 320-32	59.2	85
113	Peginesatide in patients with anemia undergoing hemodialysis. <i>New England Journal of Medicine</i> , 2013 , 368, 307-19	59.2	75
112	Guideline for the laboratory diagnosis of functional iron deficiency. <i>British Journal of Haematology</i> , 2013 , 161, 639-48	4.5	209
111	Peginesatide for anemia in chronic kidney disease. <i>New England Journal of Medicine</i> , 2013 , 368, 1553-4	59.2	2
110	Effect of red cell transfusions on future kidney transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 852-60	6.9	55
109	Iron status in patients with chronic heart failure. <i>European Heart Journal</i> , 2013 , 34, 827-34	9.5	154
108	Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. <i>European Heart Journal</i> , 2013 , 34, 816-29	9.5	230
107	How important is transfusion avoidance in 2013?. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28, 1092-9	4.3	36
106	Iron deficiency: what are the future trends in diagnostics and therapeutics?. <i>Clinical Chemistry</i> , 2013 , 59, 740-5	5.5	16
105	Exercise therapy in individuals with chronic kidney disease: a systematic review and synthesis of the research evidence. <i>Annual Review of Nursing Research</i> , 2013 , 31, 235-75	0.7	31

104	Fatal and Serious Anaphylaxis Following Peginesatide Administration. <i>Blood</i> , 2013 , 122, 5612-5612	2.2	
103	Use of intravenous iron supplementation in chronic kidney disease: an update. <i>Iranian Journal of Kidney Diseases</i> , 2013 , 7, 9-22	0.9	37
102	New anemia therapies: translating novel strategies from bench to bedside. <i>American Journal of Kidney Diseases</i> , 2012 , 59, 444-51	7.4	43
101	Laparoscopic sleeve gastrectomy is a novel and effective treatment for obesity in patients with chronic kidney disease. <i>Obesity Surgery</i> , 2012 , 22, 119-23	3.7	37
100	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 3923-9	4.3	16
99	Serum hemojuvelin and hepcidin levels in chronic kidney disease. <i>American Journal of Nephrology</i> , 2012 , 35, 295-304	4.6	20
98	Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. <i>Kidney International</i> , 2012 , 81, 727-32	9.9	79
97	Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). <i>Journal of General Internal Medicine</i> , 2012 , 27, 1697-703	4	25
96	Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. <i>Pharmaceutical Research</i> , 2012 , 29, 1454-67	4.5	131
95	A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 783-96	5.3	30
94	Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. <i>European Journal of Heart Failure</i> , 2012 , 14, 882-6	12.3	54
93	Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 50-7	4.3	13
92	Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease. <i>American Journal of Hypertension</i> , 2012 , 25, 1024-9	2.3	20
91	Vascular access for hemodialysis in the elderly. <i>Journal of Vascular Surgery</i> , 2011 , 53, 1039-43	3.5	42
90	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2011 , 8, 485-93	14.8	132
89	Erythropoietic therapy: time for some changes. <i>Journal of Renal Nursing</i> , 2011 , 3, 6-9		
88	Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 845-55	6.9	43
87	Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2579-86	6.9	24

86	Iron supplementation in nephrology and oncology: what do we have in common?. <i>Oncologist</i> , 2011 , 16 Suppl 3, 25-34	5.7	21
85	Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?. <i>Current Medical Research and Opinion</i> , 2010 , 26, 473-82	2.5	49
84	Hemoglobin variability does not predict mortality in European hemodialysis patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 1765-75	12.7	262
83	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2846-50	4.3	110
82	Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 4009-17	4.3	64
81	Current status of the measurement of blood hepcidin levels in chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 1681-9	6.9	59
80	Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 914-9	4.3	9
79	Neutrophil gelatinase-associated lipocalin and hepcidin: what do they have in common and is there a potential interaction?. <i>Kidney and Blood Pressure Research</i> , 2010 , 33, 157-65	3.1	25
78	Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study. <i>Current Medical Research and Opinion</i> , 2010 , 26, 2543-52	2.5	7
77	Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 69-76	7.4	69
76	Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 2651-60	12.7	90
75	A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. <i>New England Journal of Medicine</i> , 2009 , 361, 1848-55	59.2	126
74	Biosimilar epoetins. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1698-9; author reply 1699-700	4.3	3
73	Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1176-82	6.9	34
72	Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. <i>Advances in Chronic Kidney Disease</i> , 2009 , 16, 117-30	4.7	59
71	Evolution of iv iron compounds over the last century. <i>Journal of Renal Care</i> , 2009 , 35 Suppl 2, 8-13	1.6	35
70	Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2971-6	2.5	6
69	Effect of computer-assisted European Best Practice Guideline implementation on adherence and target attainment: ORAMA results. <i>Journal of Nephrology</i> , 2009 , 22, 662-74	4.8	8

68	Erythropoietins: a common mechanism of action. <i>Experimental Hematology</i> , 2008 , 36, 1573-84	3.1	181
67	Novel erythropoiesis-stimulating agents: a new era in anemia management. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 200-7	6.9	83
66	Pure red cell aplasia induced by erythropoiesis-stimulating agents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 193-9	6.9	67
65	Renal anemia: comparing current Eastern and Western European management practice (ORAMA). <i>Renal Failure</i> , 2008 , 30, 267-76	2.9	10
64	C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 337-47	6.9	82
63	A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 263-8	4.3	49
62	Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. <i>Current Opinion in Investigational Drugs</i> , 2008 , 9, 1034-47		13
61	Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial. <i>Trials</i> , 2007 , 8, 35	2.8	3
60	Optimal Iron Management in Patients Receiving Erythropoietin Therapy. <i>Seminars in Dialysis</i> , 2007 , 11, 10-13	2.5	3
59	Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe. <i>American Journal of Kidney Diseases</i> , 2007 , 50, 358-61	7.4	4
58	Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe?. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 2738-42	4.3	20
57	Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 784-93	4.3	35
56	Epoetin-induced pure red cell aplasia: diagnosis and treatment. <i>Current Opinion in Nephrology and Hypertension</i> , 2007 , 16, 585-8	3.5	12
55	Pharmacology of darbepoetin alfa. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22 Suppl 4, iv2-iv9	4.3	26
54	How to optimise anaemia therapy in peritoneal dialysis patients. <i>Contributions To Nephrology</i> , 2006 , 150, 202-213	1.6	6
53	Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 2963-5	4.3	28
52	Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006 , 1, 1211-5	6.9	153
51	Iron and the anaemia of chronic disease: a review and strategic recommendations. <i>Current Medical Research and Opinion</i> , 2006 , 22, 731-7	2.5	64

50	Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. <i>Lancet, The</i> , 2006 , 368, 947-53	40	123
49	Normalization of hemoglobin level in patients with chronic kidney disease and anemia. <i>New England Journal of Medicine</i> , 2006 , 355, 2071-84	59.2	1576
48	Recent advances in erythropoietic agents in renal anemia. <i>Seminars in Nephrology</i> , 2006 , 26, 313-8	4.8	38
47	Experience With Intravenous Iron in Nephrology. <i>Seminars in Hematology</i> , 2006 , 43, S9-S12	4	6
46	Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. <i>Transplantation</i> , 2006 , 81, 1112-8	1.8	87
45	Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)?. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20 Suppl 8, viii18-21	4.3	4
44	The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. <i>American Journal of Kidney Diseases</i> , 2005 , 45, 381-7	7.4	19
43	Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. <i>American Journal of Kidney Diseases</i> , 2005 , 46, 283-9	7.4	53
42	Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20 Suppl 4, iv9-15	4.3	54
41	Hematide[α Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).. <i>Blood</i> , 2005 , 106, 3532-3532	2.2	6
40	CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. <i>Psychophysiology</i> , 2005 , 4, 436-40		114
39	Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. <i>Current Medical Research and Opinion</i> , 2004 , 20, 83-6	2.5	34
38	Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 288-93	4.3	68
37	Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1877-82	12.7	74
36	Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients?. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19 Suppl 5, V73-78	4.3	22
35	Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 2901-5	4.3	12
34	Over 5 years of darbepoetin alfa: two case histories. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 951-4	4	1
33	Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. <i>Lancet, The</i> , 2004 , 363, 1768-71	40	112

32	Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. <i>Journal of the American Society of Nephrology: JASN</i> , 2003 , 14, 1776-84	12.7	106
31	Once-weekly erythropoietic therapy: is there a difference between the available preparations?. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 36viii-36	4.3	
30	Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 133-40	4.3	16
29	Predialysis Survey on Anemia Management: patient referral. <i>American Journal of Kidney Diseases</i> , 2003 , 41, 49-61	7.4	30
28	Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 576-81	4.3	46
27	Erythropoietin treatment in the neuropsychiatric porphyrias. <i>Clinica Chimica Acta</i> , 2003 , 338, 61-6	6.2	4
26	PRE-dialysis survey on anaemia management. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 89-100	4.3	85
25	CREATE: new strategies for early anaemia management in renal insufficiency. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18 Suppl 2, ii13-6	4.3	6
24	Erythropoietin and renal failure. <i>Psychophysiology</i> , 2003 , 2, 459-64		4
23	Once-weekly erythropoietic therapy: is there a difference between the available preparations?. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 2047-51	4.3	13
22	Darbepoetin alfa: a new therapeutic agent for renal anemia. <i>Kidney International</i> , 2002 , 55-61	9.9	27
21	Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17 Suppl 11, 39-43	4.3	245
20	The inflammatory response and epoetin sensitivity. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17 Suppl 1, 48-52	4.3	140
19	Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17 Suppl 5, 66-70	4.3	85
18	Serum erythropoietin levels may be inappropriately low in the acute neuropsychiatric porphyrias. <i>Clinica Chimica Acta</i> , 2002 , 317, 93-100	6.2	5
17	Ace inhibitors and erythropoietin responsiveness. <i>American Journal of Kidney Diseases</i> , 2001 , 38, 649-51	7.4	12
16	Intravenous iron sucrose: establishing a safe dose. <i>American Journal of Kidney Diseases</i> , 2001 , 38, 988-91	7.4	145
15	Darbepoetin Alfa: A Viewpoint by Iain C. Macdougall. <i>Drugs</i> , 2001 , 61, 2105-2106	12.1	1

14	An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). <i>Nephrology Dialysis Transplantation</i> , 2001 , 16 Suppl 3, 14-21	4.3	61
13	Should the hematocrit be normalized in dialysis and in pre-ESRD patients?. <i>Blood Purification</i> , 2001 , 19, 157-67	3.1	7
12	Individualizing target haemoglobin concentrations--tailoring treatment for renal anaemia. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16 Suppl 7, 9-14	4.3	10
11	Intravenous administration of iron in epoetin-treated haemodialysis patients--which drugs, which regimen?. <i>Nephrology Dialysis Transplantation</i> , 2000 , 15, 1743-5	4.3	34
10	Higher target haemoglobin level and early anaemia treatment: different or complementary concepts?. <i>Nephrology Dialysis Transplantation</i> , 2000 , 15 Suppl 3, 3-7	4.3	5
9	Metabolic adjuvants to erythropoietin therapy. <i>Mineral and Electrolyte Metabolism</i> , 1999 , 25, 357-64		3
8	The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. <i>Nephrology Dialysis Transplantation</i> , 1999 , 14, 1836-41	4.3	100
7	Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. <i>American Journal of Kidney Diseases</i> , 1999 , 34, s40-s46	7.4	47
6	Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. <i>Journal of the American Society of Nephrology: JASN</i> , 1999 , 10, 2392-5	12.7	337
5	Optimizing erythropoietin therapy. <i>Current Opinion in Hematology</i> , 1999 , 6, 121-6	3.3	5
4	A randomized controlled study of iron supplementation in patients treated with erythropoietin. <i>Kidney International</i> , 1996 , 50, 1694-9	9.9	280
3	Treatment of renal anemia with recombinant human erythropoietin. <i>Current Opinion in Nephrology and Hypertension</i> , 1992 , 1, 210-9	3.5	16
2	Rheological studies during treatment of renal anaemia with recombinant human erythropoietin. <i>British Journal of Haematology</i> , 1991 , 77, 550-8	4.5	18
1	Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). <i>Clinical Pharmacokinetics</i> , 1991 , 20, 99-113	6.2	102